VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ANABAnaptysBio, Inc.
$58.48$2.5B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksANABP/E History

ANAB logoAnaptysBio, Inc. (ANAB) P/E Ratio History

Deep Value

Trading at -127.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2021–2021

Current P/E (TTM)
-127.1x
-321% vs 5Y avg
5Y Avg P/E
57.5x
Median 57.5x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$-0.93
Price$58.48
Earnings YieldN/A
EPS Growth (1Y)91.0%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 25, 2026, AnaptysBio, Inc. (ANAB) trades at a price-to-earnings ratio of -127.1x, with a stock price of $58.48 and trailing twelve-month earnings per share of $-0.93.

The current P/E is 321% below its 5-year average of 57.5x. Over the past five years, ANAB's P/E has ranged from a low of 57.5x to a high of 57.5x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.5x, ANAB trades at a 665% discount to its sector peers. The sector includes 232 companies with P/E ratios ranging from 0.0x to 192.0x.

Relative to the broader market, ANAB trades at a notable discount to the S&P 500 median P/E of 24.7x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ANAB DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ANAB Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-127.1vs22.5
-665%
Below Sector
vs. S&P 500
-127.1vs24.7
-614%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 91% EPS growth (1Y)

ANAB P/E vs Peers

Immunology and Inflammation Therapies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$65B15.02.37+8%
ABBV logoABBVAbbVie Inc.
$415B99.1--1%
LLY logoLLYEli Lilly and Company
$1.1T48.71.69+96%
GSK logoGSKGSK plc
$103B7.0Lowest0.49Best+348%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ANAB Historical P/E Data (2021–2021)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2021 Q3-$18.08$0.3157.5x+0%

Average P/E for displayed period: 57.5x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

5+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ANAB — Frequently Asked Questions

Quick answers to the most common questions about buying ANAB stock.

What is ANAB's P/E ratio?

AnaptysBio, Inc. (ANAB) trailing twelve-month P/E ratio is -127.1x, based on TTM diluted EPS of $-0.93. The 5-year average P/E is 57.5x and the historical range spans 57.5x to 57.5x.

Is ANAB stock overvalued or undervalued?

ANAB trades at -127.1x P/E, below its 5-year average of 57.5x. At the 0th percentile of its historical range (57.5x–57.5x), the stock is priced at a discount to its own history.

Is ANAB stock expensive?

No, ANAB is not expensive on a historical basis. The current P/E of -127.1x is below the 5-year average of 57.5x and sits at the 0th percentile of its valuation range.

What is ANAB's historical P/E range?

Over the past 5 years, ANAB's P/E ratio has ranged from 57.5x to 57.5x, with a median of 57.5x and an average of 57.5x. The current P/E of -127.1x places the stock at the 0th percentile of this range. Full historical data spans 2021–2021.

How does ANAB's P/E compare to the S&P 500?

ANAB trades at -127.1x P/E versus the S&P 500 median of 24.7x. The 615% discount to the market suggests lower growth expectations or perceived higher risk.

How does ANAB's valuation compare to Healthcare peers?

AnaptysBio, Inc. P/E of -127.1x compares to the Healthcare sector median of 22.5x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ANAB's PEG ratio?

ANAB PEG ratio is N/A, based on a P/E of -127.1x and EPS growth of 91.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ANAB's earnings yield?

ANAB earnings yield is N/A, the inverse of its -127.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ANAB P/E Ratio History (2021–2021)

Quarterly valuation multiple from closing price and trailing EPS

Current57.5x
Period Avg57.5x
Range57.5x - 57.5x
Change+0%
1 quartersSep 30, 2021 - Sep 30, 2021